Authority in the Field of Molecular Hydrogen
Together with Czech experts, we are officially launching the first clinical study in the Czech Republic focused on the use of molecular hydrogen in patients with mild cognitive impairment (MCI).
January 19, 2026 – start of the clinical study
January 22, 2026 at 2:00 PM – press conference at ČTK Prague (media and partners are welcome)
As Professor Ohta stated:
“…together with the team in the Czech Republic, we want to help establish a standardized pathway toward regulatory registration for this field.”
And our goal is clear: to clinically verify, standardize, and move this technology into the EU regulatory framework, and subsequently open the door to international cooperation, clinical partners, and strategic investors.
Full article here: Vědecká autorita z Japonska, profesor Shigeo Ohta, přicestoval do Česka: skupina H2 Global Group spouští v ČR klinickou studii s molekulárním vodíkem - Metro.cz
